<DOC>
	<DOCNO>NCT00550810</DOCNO>
	<brief_summary>The major goal determine whether experimental agent clinically promising activity would merit progression formal phase III trial . Patients hormone refractory prostate cancer docetaxel chemotherapy limit treatment option systemic treatment proven effective . Because action , safety simple administration SU011248 potential effectiveness disease set . Promising activity study would provide necessary proof-of-principle large confirmatory study population , potentially early stage common disease .</brief_summary>
	<brief_title>Sutent Maintenance After Response Taxotere</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histological cytological diagnosis adenocarcinoma prostate Metastatic locally recurrent disease curable standard therapy ECOG performance status 0 , 1 2 Prior single agent docetaxel docetaxel combination chemotherapy document PSA image response , objective evidence disease progression study enrolment Patients history invasive cancer , except adequately treat non melanoma skin cancer . Patients know brain metastasis . History allergic reaction attribute compound similar chemical biologic composition SU011248 . Other serious intercurrent illness medical condition might aggravate protocol treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Sutent</keyword>
</DOC>